89bio Ltd., of San Francisco, reported preclinical data on BIO89-100, a long-acting glycopegylated fibroblast growth factor 21 analogue, at the Annual Meeting of the European Association for the Study of the Liver in Vienna. In spontaneously diabetic obese cynomolgus monkeys, the drug produced statistically significant reductions in body weight, fasting plasma glucose, LDL cholesterol, triglycerides and hemoglobin A1c compared to the vehicle group.